This link will take you to a page that’s not on LinkedIn

Because this is an external link, we’re unable to verify it for safety.

https://www.medinews.it/comunicati/tumore-della-vescica-muscolo-invasivo-pembrolizumab-piu-enfortumab-vedotin-somministrati-prima-e-dopo-la-chirurgia-riducono-del-60-il-rischio-di-insorgenza-di-nuovi-eventi-e-del-50-il-rischio-di/